Antibiotic Resistance Market Report 2026

The antibiotic resistance market size has grown strongly in recent years. It will grow from $12.85 billion in 2025 to $13.73 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to widespread antibiotic misuse, increasing hospital-acquired infections, expansion of broad-spectrum antibiotic use, limited availability of novel antibiotics, rising prevalence of resistant pathogens.

The antibiotic resistance market size is expected to see strong growth in the next few years. It will grow to $18.22 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing investments in antimicrobial R&D, growing adoption of precision diagnostics, expansion of global resistance surveillance networks, rising focus on alternative therapies, increasing public-private partnerships. Major trends in the forecast period include increasing focus on novel antibiotic development, rising adoption of combination drug therapies, growing use of rapid diagnostic testing, expansion of antimicrobial stewardship programs, enhanced surveillance of resistant pathogens.

The increasing prevalence of drug-resistant infections is expected to drive the growth of the antibiotic-resistance market in the coming years. Drug-resistant infections are illnesses caused by bacteria that no longer respond to standard treatments, making these infections significantly harder or sometimes impossible to cure. Antimicrobial resistance drugs aid in managing various drug-resistant infections by improving antibiotic treatment outcomes for both target and nontarget pathogens, depending on the specific resistance mechanisms and the structure of microbiome interactions. For example, in November 2025, according to the UK Health Security Agency, a UK-based government body responsible for health security in England, the number of deaths among patients with antibiotic-resistant infections increased from 2,041 in 2023 to 2,379 in 2024, representing a rise of 338 deaths within a single year. Consequently, the rise in drug-resistant infections is propelling the growth of the antibiotic-resistance market.

Major companies operating in the antibiotic resistance market are concentrating on developing innovative products to improve treatment outcomes, ensure patient safety, and tackle the increasing problem of multi-drug resistant (MDR) infections. For example, in January 2023, Alkem Laboratories Limited, an India-based pharmaceutical company, launched Zidavi, a novel antibiotic aimed at combating MDR infections, enhancing availability, affordability, and accessibility while saving the lives of critically ill patients. Zidavi is a distinctive combination of ceftazidime and avibactam capable of treating infections caused by MDR gram-negative pathogens. Supplied as a sterile powdered concentrate for reconstitution, each single-dose vial contains ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam. It offers an effective option for managing hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) caused by meropenem- and colistin-resistant pathogens.

In June 2024, Eli Lilly and Co., a US-based pharmaceutical company focused on antimicrobial resistance, partnered with OpenAI to advance healthcare through AI-driven innovation. Through this collaboration, Lilly aims to accelerate the discovery and development of medicines targeting drug-resistant bacteria by leveraging OpenAI’s generative AI technologies and enhancing its technological capabilities in antimicrobial research. OpenAI is a US-based provider of artificial intelligence technologies and generative AI solutions.

Major companies operating in the antibiotic resistance market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Merck and Co. Inc., Bristol-Myers Squibb, Sanofi S.A., AstraZeneca, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Theravance Biopharma Inc., Nabriva Therapeutics Plc, Seres Therapeutics Inc., Armata Pharmaceuticals Inc.

North America was the largest region in the antibiotic resistance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotic resistance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibiotic resistance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the antibiotic resistance market by increasing costs of imported active pharmaceutical ingredients, laboratory reagents, diagnostic systems, and advanced manufacturing equipment used in antibiotic development. Pharmaceutical companies and hospitals in North America and Europe are most affected due to reliance on global API supply chains, while Asia-Pacific faces cost pressure on antibiotic exports. These tariffs raise drug development and treatment costs. However, they also encourage domestic API production, regional manufacturing diversification, and long-term resilience in antimicrobial supply chains.

The antibiotic resistance market research report is one of a series of new reports that provides antibiotic resistance market statistics, including antibiotic resistance industry global market size, regional shares, competitors with a antibiotic resistance market share, detailed antibiotic resistance market segments, market trends and opportunities, and any further data you may need to thrive in the antibiotic resistance industry. This antibiotic resistance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antimicrobial resistance occurs when microorganisms, including bacteria and fungi, develop the ability to withstand medications intended to eliminate them. This resistance makes infections difficult to treat, potentially resulting in the death of the affected individual in severe cases.

The main antibiotic-resistance drug classes include beta-lactam antibiotics, cephalosporins, quinolone antibiotics, macrolide antibiotics, tetracyclines, oxazolidinones, and others. Beta-lactam antibiotics are compounds containing a beta-lactam ring in their chemical structure, which function by preventing bacterial cell wall synthesis through covalent binding to key penicillin-binding proteins (PBPs), thereby inhibiting the growth of organisms. The pathogens involved include Staphylococcus aureus, Streptococcus pneumoniae, Neisseria gonorrhoeae, Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Shigella, Clostridium difficile, and others, which are implicated in conditions such as urinary tract infections, intra-abdominal infections, bloodstream infections, Clostridium difficile infections, and more. The mechanisms include protein synthesis inhibition, cell wall synthesis inhibition, RNA synthesis inhibition, DNA synthesis inhibition, and others, and these drugs are utilized by various end users, including hospitals, homecare settings, specialty clinics, and others.

The antibiotic resistance market consists of sales of antibiotic drug classes such as carbapenems, glycopeptide antibiotics, penicillin, fluoroquinolones, trimethoprim-sulfamethoxazole, lincosamides, aminoglycosides, polymyxins, and nitroimidazoles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.